Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia. Issue 8 (3rd August 2015)

• Record Type: Journal Article
• Authors: Chantepie, Sylvain P.; Reboursiere, Emilie; Mear, Jean-Baptiste; Gac, Anne-Claire; Salaun, Veronique; Benabed, Khaled; Cheze, Stéphane; Johnsonansah, Hyacinthe; Macro, Margaret; Vilque, Jean-Pierre; Reman, Oumedaly
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 8(2015:Aug.)
• Page Start: 2326
• Page End: 2330
• Publication Date: 2015-08-03
• Subjects: Myeloid leukemias and dysplasias -- chemotherapeutic approaches -- clinical results; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.986478
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract : The prognosis of refractory/relapsed acute myeloid leukemia (AML) remains poor. The complete response (CR) rate after relapse is around 25%, with 11% of patients still alive after 5 years. The efficacy and toxicity of fractionated gemtuzumab ozogamicin (fGO; 3 mg/m 2, days 1, 4, 7) in combination with intensive chemotherapy were retrospectively evaluated in patients with refractory/relapsed AML. Thirty-six patients (median age 54 years) were included. European LeukemiaNet classification was as follows: favorable ( n = 6), intermediate-I ( n = 13), intermediate-II ( n = 8), adverse ( n = 9). Median CR duration was 7.16 months (1.63–96.8). The overall response rate was 38.8%, with CR in eight patients (22.2%) and CR with incomplete platelet recovery (CRp) in six patients (16.7%). Two-year overall survival was 26% (95% confidence interval [CI]: 12–42) and 2-year relapse free-survival was 18.5% (95% CI: 6.6–35.0). Salvage therapy with fractionated GO in patients with very high-risk disease produced a 38.8% response rate and may be considered as a bridge therapy to transplant.